Registration for a live webinar on 'Rare disease clinical trials: challenges and best practices' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- HPV infection
- HPV causes anogenital and H&N tumors
- HPV-based prevention strategies
- HPV prevalence among normal cytology women
- Global cervical cancer prevalence
- HPV induced lesions & cancers express E6 & E7
- Cell-mediated immune response to HPV16
- License to kill: T cell activation
- HPV-induced diseases: therapeutic vaccine
- Synthetic Long Peptide (SLP) vaccine concept
- HPV16 vaccine is composed of long peptides
- Phase I, end stage cervical cancer
- ISA101 clinical proof-of-concept in VIN
- Excellent clinical response in VIN, phase II study
- VIN phase II ISA101 vaccination overcomes anergy
- Histology of completely cleared VIN lesion
- SLP vaccine vs. others
- Combining chemotherapy & SLP vaccination
- Combined cisplatin + SLP treatment
- HPV16+ tumor chemo-immunotherapy
- Weight loss upon treatment with cisplatin
- TNF + cisplatin synergy
- Inhibition of synergy in tumor eradication
- CervISA: Phase I/II ISA101 in cervical cancer
- Overall conclusions
Topics Covered
- HPV infection & prevention strategies
- Global cervical cancer prevalence
- HPV induced lesions & cancers
- Cell-mediated immune response to HPV
- Synthetic Long Peptide (SLP) vaccine concept
- Vulval intraepithelial neoplasia (VIN) vaccine
- Combining chemotherapy & SLP vaccination
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Melief, C. (2015, May 31). Cancer vaccines 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 30, 2024, from https://doi.org/10.69645/TKGF1444.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Cornelis Melief, Consultant: I am CSO of ISA pharmaceuticals Stock Shareholder (self-managed): I have Stock Appreciation Rights in ISA pharmaceuticals
Cancer vaccines 2
Published on May 31, 2015
34 min
Other Talks in the Series: Immunotherapy of Cancer
Other Talks in the Series: Vaccines
Transcript
Please wait while the transcript is being prepared...
0:04
We now will
discuss in more detail, cancers
caused by human papilloma virus.
Here you see, the uterus
of a patient and a vagina
and the cervix, where this virus
strikes to establish itself
first in a persistent infection.
And after many years the virus
can cause premalignant lesions.
And after a couple more years,
you then develop cancer.
In the middle you see the virus.
And the yellow structure on this
virus indicates the L1 protein.
And vaccinating
against the L1 protein
folded as a virus-like particle
induces neutralizing antibodies
that are characteristic for the
two preventive vaccines that
are currently marketed,
Cervarix and Guardasil.
1:02
HPV causes anogenital and
head and neck cancers.
More than half of
all of these lesions
are caused by high-risk
HPV16, which causes
75% of vulva preneoplastic
premalignant lesions, more than 75%
of anal neoplasias,
but also more than 75%
of oropharyngeal head
and neck cancers.
In the case of cervical cancer
the implication of HPV16
is somewhat lower, but still
about 50% of involvement
in the causations of cervical
cancer and high-grade cervical
intraepithelial neoplasia, or CIN.
And there are unmet medical needs
also for the premalignant lesions.
VIN, CIN, PIN is penile, and AIN
in the US, Europe, and Japan.
And currently, even for
these premalignant lesions
there is no satisfactory treatment,
because the surgery is mutilating
and there are higher
recurrence rates.